NCT05806931View on ClinicalTrials.gov

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2027

Conditions
Colon CancerRectal Cancer
Interventions
DRUG

TAS-102, oxaliplatin, irinotecan with bevacizumab

Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.

Trial Locations (9)

07202

RECRUITING

Trinitas Hospital and Comprehensive Cancer Center, Elizabeth

07302

RECRUITING

RWJBarnabas Health Jersey City Medical Center, Jersey City

08701

RECRUITING

RWJBarnabas Health - Monmouth Medical Center Southern Campus, Lakewood

07039

RECRUITING

Cooperman Barnabas Medical Center (Saint Barnabas Medical Center), Livingston

07740

RECRUITING

RWJBarnabas Health - Monmouth Medical Center, Long Branch

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

RECRUITING

RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick

08873

RECRUITING

RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset

08755

RECRUITING

RWJBarnabas Health - Community Medical Center, Toms River

All Listed Sponsors
lead

Rutgers, The State University of New Jersey

OTHER